Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: A mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis

Arthritis and Rheumatism

Volumn 44, Issue 1, 2001, Pages 138-150

  Mason, Justin C ^a   Lidington, Elaine A ^a   Yarwood, Helen ^a   Lublin, Douglas M ^b   Haskard, Dorian O ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECAY ACCELERATING FACTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1H4; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL PROTECTION; COMPLEMENT ACTIVATION; CYTOLYSIS; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; INJURY; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RHEUMATIC DISEASE; STEADY STATE; UMBILICAL VEIN;

ANTIGENS, CD55; CELL SURVIVAL; COMPLEMENT SYSTEM PROTEINS; CYTOPROTECTION; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; HUMANS; LYMPHOKINES; MALE; MICROCIRCULATION; MITOGEN-ACTIVATED PROTEIN KINASES; NEOVASCULARIZATION, PATHOLOGIC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE C; RNA, MESSENGER; SKIN; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035150353     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200101)44:1<138::AID-ANR18>3.0.CO;2-G     Document Type: Article

References (67)

1. Complement membrane attack on nucleate cells: Resistance, recovery and non-lethal effects
2. Renal localization of the membrane attack complex in systemic lupus erythematosus nephritis
3. The ninth complement component in rheumatoid arthritis, Behcet's disease and other rheumatic diseases
4. Measurement of terminal complement complexes in rheumatoid arthritis
5. Decay-accelerating factor: Biochemistry, molecular biology and function
6. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement mediated lysis
7. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system
8. Membrane cofactor protein (MCP or CD46): Newest member of the regulators of the complement activation gene cluster
9. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells
10. Decay-accelerating factor is present on cultured human umbilical vein endothelial cells
11. Membrane cofactor protein of complement is present on human fibroblast, epithelial, and endothelial cells
12. Control of the complement system
13. Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition
14. Angiogenesis: Implications for rheumatoid arthritis
15. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis
16. Microvascular deposition of complement membrane attack complex in dermatomyositis
17. Expression of decay-accelerating factor on synovial lining cells in inflammatory and degenerative arthritides
18. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface
19. Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1
20. Complement-mediated regulation of tissue factor activity in endothelium
21. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity
22. Phorbol esters increase synthesis of decay-accelerating factor, a phosphatidylinositol-anchored surface protein, in human endothelial cells
23. Characterization of vascular endothelial cell growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth
24. Protein kinase C β1 overexpression augments phorbol ester-induced increase in endothelial permeability
25. Potent selective inhibitors of protein kinase C
26. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo
27. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
28. A monoclonal antibody that detects a novel antigen on endothelial cells that is induced by tumor necrosis factor, IL-1, or lipopolysaccharide
29. Human Thy-1 is cytokine inducible on vascular endothelial cells and is a signaling molecule regulated by protein kinase C
30. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
31. Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement
32. Expression and regulation of complement regulatory proteins CD59 and decay-accelerating factor (DAF) on endothelial cells
33. VEGFs, receptors and angiogenesis
34. Human umbilical vein and dermal microvascular endothelial cells show heterogeneity in response to activation of protein kinase C
35. Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins
36. Endoglin: A 180-kD endothelial cell and macrophage restricted differentiation molecule
37. Enhanced expression of decay accelerating factor and CD59/homologous restriction factor 20 on the colonic epithelium of ulcerative colitis
38. Altered expression of membrane inhibitors of complement in human gastric epithelium during Helicobacter-associated gastritis
39. Structure and function of decay accelerating factor CD55
40. Localization of decay accelerating factor in normal and diseased kidneys
41. Membrane regulators of complement activation and their aberrant expression in disease
42. Induction of decay accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury
43. Decay-accelerating factor is a component of subendothelial extracellular matrix in vitro and is augmented by activation of protein kinase C
44. Complement activation occurs on subendothelial extracellular matrix
45. Vascular permeability factor/vascular endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins
46. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes
47. Adenosine A1 receptor induced delayed preconditioning in rabbits: Induction of p38 mitogen-activated protein kinase activation and Hsp27 phosphorylation via a tyrosine kinase- and protein kinase C-dependent mechanism
48. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic flbroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin
49. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells
50. One-way cross-talk between p38(MAPK) and p42/44(MAPK): Inhibition of p38(MAPK) induces low density lipoprotein receptor expression through activation of the p42/44(MAPK) cascade
51. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis
52. Stereo-specific activation of the complement system by phosphatidylserine appearing on apoptotic cells
53. The globular heads of C1q bind specifically to surface blebs of apoptotic human endothelial cells: Implications for immune tolerance
54. Activation of the alternative path way of human complement by apoptotic human umbilical vein endothelial cells
55. Relative inefficiency of terminal complement activation
56. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis
57. The seven-span transmembrane receptor CD97 has a cellular ligand (CD55 DAF)
58. Expression characteristics of the human CD97 antigen
59. Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue
60. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
61. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody
62. Vascular endothelial growth factor: A cytokine modulating endothelial function in rheumatoid arthritis
63. Vascular permeability factor/endothelial growth factor (VPF/VEGF): Accumulation and expression in human synovial fluids and rheumatoid synovial tissue
64. Angiogenesis: A critical process in the pathogenesis of RA - A role for VEGF?
65. VEGF(165) mediates glomerular endothelial repair
66. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Ak signal transduction pathway: Requirement for Flk/KDR activation
67. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells